PMID- 35035357
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220118
IS  - 1664-042X (Print)
IS  - 1664-042X (Electronic)
IS  - 1664-042X (Linking)
VI  - 12
DP  - 2021
TI  - Autologous Bone Marrow Cell Infusion for the Treatment of Decompensated Liver 
      Cirrhosis Patients With Type 2 Diabetes Mellitus.
PG  - 730797
LID - 10.3389/fphys.2021.730797 [doi]
LID - 730797
AB  - This study aimed to indicate whether autologous bone marrow cell infusion (ABMI) 
      via the right omental vein (ROV) could have a regulatory effect on decompensated 
      liver cirrhosis (DLC) patients with type 2 diabetes mellitus (T2DM). For this 
      purpose, 24 DLC patients with T2DM were divided into observation group (n=14) and 
      control group (n=10). Patients in the observation group were given ABMI through 
      the ROV and right omental artery (ROA), and cases in the control group received 
      ABMI through the ROV. At 1, 3, 6, and 12months after ABMI, it was revealed that 
      the prothrombin time, the total bilirubin levels, and the amount of ascites were 
      significantly lower, while the serum albumin levels in the two groups were 
      markedly higher compared with those before ABMI (p<0.01), and there was no 
      significant difference between the two groups at each time point (p>0.05). The 
      fasting blood glucose and glycosylated hemoglobin levels at 6 and 12months after 
      ABMI in the two groups significantly decreased compared with those before ABMI 
      (p<0.05 or p<0.01), while the decreased levels in the observation group were more 
      obvious than those in the control group at each time point (p<0.01). The amount 
      of insulin in the observation group at 3, 6, and 12months after ABMI was 
      significantly less than that before ABMI in the control group (p<0.01). In 
      summary, ABMI showed a significant therapeutic efficacy for DLC patients with 
      T2DM through ROV and ROA.
CI  - Copyright (c) 2021 Liu, Cheng, Lang, Li, Si and Wang.
FAU - Liu, Baochi
AU  - Liu B
AD  - Department of Surgery, Shanghai Public Health Clinical Center, Fudan University, 
      Shanghai, China.
FAU - Cheng, Mingrong
AU  - Cheng M
AD  - Department of Anorectal Surgery, Panzhou People's Hospital, Guizhou, China.
AD  - Shanghai New Hongqiao International Medical Center, Shanghai, China.
FAU - Lang, Lin
AU  - Lang L
AD  - Department of General Surgery, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
FAU - Li, Lei
AU  - Li L
AD  - Department of Surgery, Shanghai Public Health Clinical Center, Fudan University, 
      Shanghai, China.
FAU - Si, Yanhui
AU  - Si Y
AD  - Department of Surgery, Shanghai Public Health Clinical Center, Fudan University, 
      Shanghai, China.
FAU - Wang, Guangmian
AU  - Wang G
AD  - Shanghai New Hongqiao International Medical Center, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20211118
PL  - Switzerland
TA  - Front Physiol
JT  - Frontiers in physiology
JID - 101549006
PMC - PMC8753408
OTO - NOTNLM
OT  - autologous bone marrow infusion
OT  - cell therapy
OT  - decompensated cirrhosis
OT  - surgery-related complications
OT  - type 2 diabetes
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/01/18 06:00
MHDA- 2022/01/18 06:01
PMCR- 2021/11/18
CRDT- 2022/01/17 05:53
PHST- 2021/07/14 00:00 [received]
PHST- 2021/10/26 00:00 [accepted]
PHST- 2022/01/17 05:53 [entrez]
PHST- 2022/01/18 06:00 [pubmed]
PHST- 2022/01/18 06:01 [medline]
PHST- 2021/11/18 00:00 [pmc-release]
AID - 10.3389/fphys.2021.730797 [doi]
PST - epublish
SO  - Front Physiol. 2021 Nov 18;12:730797. doi: 10.3389/fphys.2021.730797. eCollection 
      2021.